Document Detail


Novel targets for interleukin 18 binding protein.
MedLine Citation:
PMID:  11890646     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Interleukin 18 (IL18) is related to the IL1 family by structure, receptors, signalling molecules, and function. IL18 induces gene expression and synthesis of tumour necrosis factor (TNF), IL1, Fas ligand, several chemokines, and vascular adhesion molecules. Similar to IL1beta, IL18 is synthesised as a biologically inactive precursor molecule lacking a signal peptide. The IL18 precursor requires cleavage into an active, mature molecule by the intracellular cysteine protease, IL1beta converting enzyme (ICE, or caspase-1). Inhibitors of ICE activity limit the biological activity of IL18 in animals and may be useful in reducing the activity of IL18 in human disease. However, a constitutively secreted IL18 binding protein (IL18BP) exists which functions as a natural inhibitor of IL18 activity. IL18BP binds IL18 with a high affinity (Kd of 400 pM) and, at equimolar ratios, inhibits 50-70% of IL18; at twofold molar excess, IL18BP neutralises nearly all IL18 activity. METHOD: IL18 was investigated for its role in human myocardial function. An ischaemia/reperfusion (I/R) model of suprafused human atrial myocardium was used to assess myocardial contractile force. RESULTS: The addition of IL18BP to the perfusate during and after I/R resulted in improved post-I/R contractile function from 35% of control to 76% with IL18BP. Also, IL18BP treatment preserved intracellular tissue creatine kinase levels (by 420%). Because active IL18 requires cleavage of its precursor form by ICE, inhibition of ICE attenuated the depression in contractile force after I/R (from 35% of control compared with 75.8% in treated atrial muscle, p<0.01). CONCLUSION: Myocardial ischaemia is a target for IL18BP and use of IL18BP may thereby reduce ischaemia-induced myocardial dysfunction.
Authors:
C A Dinarello
Related Documents :
24500786 - Clinically relevant reperfusion in acute ischemic stroke: mtt performs better than tmax...
4053136 - Effect of global vs regional ischaemia upon myocardial contractility and oxygen balance.
7582856 - Effects of 2-deoxyglucose, a metabolic inhibitor, on spontaneous contraction and adreno...
1703596 - Effects of platelet-activating factor on myocardial contraction and myocardial relaxati...
15222666 - Anemia management in heart failure: a thick review of thin data.
9576636 - The anterior inferior cerebellar artery infarcts: a clinical-magnetic resonance imaging...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  60 Suppl 3     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2002-03-13     Completed Date:  2002-04-11     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  iii18-24     Citation Subset:  IM    
Affiliation:
Department of Medicine, University Colorado Health Sciences Centre, Denver 80262, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Caspase 1 / antagonists & inhibitors,  metabolism
Chemokines / metabolism
Cytokines / metabolism
Enzyme Inhibitors / pharmacology
Fas Ligand Protein
Glycoproteins / metabolism,  pharmacology*
Heart Atria
Humans
Intercellular Signaling Peptides and Proteins
Interleukin-1 / metabolism
Interleukin-18 / antagonists & inhibitors*,  metabolism
Membrane Glycoproteins / metabolism
Myocardial Contraction
Myocardial Reperfusion Injury / immunology,  physiopathology,  prevention & control*
Myocardium / immunology*
Oligopeptides / pharmacology
Grant Support
ID/Acronym/Agency:
AI15614/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Chemokines; 0/Cytokines; 0/Enzyme Inhibitors; 0/FASLG protein, human; 0/Fas Ligand Protein; 0/Glycoproteins; 0/Intercellular Signaling Peptides and Proteins; 0/Interleukin-1; 0/Interleukin-18; 0/Membrane Glycoproteins; 0/Oligopeptides; 0/interleukin-18 binding protein; 0/tyrosyl-valyl-alanyl-aspartal; EC 3.4.22.36/Caspase 1
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional geno...
Next Document:  Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoi...